AstraZeneca PLC (AZN)
162.67
-1.85
(-1.12%)
USD |
NYSE |
Aug 28, 16:00
162.67
0.00 (0.00%)
After-Hours: 20:00
AstraZeneca Cash from Operations (Quarterly) : 3.420B for March 31, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 3.420B |
| December 31, 2025 | 2.405B |
| September 30, 2025 | 5.202B |
| June 30, 2025 | 3.509B |
| March 31, 2025 | 3.78B |
| December 31, 2024 | 2.969B |
| September 30, 2024 | 3.458B |
| June 30, 2024 | 3.198B |
| March 31, 2024 | 2.579B |
| December 31, 2023 | 2.459B |
| September 30, 2023 | 3.188B |
| June 30, 2023 | 1.785B |
| March 31, 2023 | 3.20B |
| December 31, 2022 | 2.432B |
| September 30, 2022 | 2.946B |
| June 30, 2022 | 1.255B |
| March 31, 2022 | 3.235B |
| December 31, 2021 | 1.424B |
| September 30, 2021 | 1.72B |
| June 30, 2021 | 895.00M |
| March 31, 2021 | 1.958B |
| December 31, 2020 | 1.802B |
| September 30, 2020 | 1.828B |
| June 30, 2020 | 1.049B |
| March 31, 2020 | 167.00M |
| Date | Value |
|---|---|
| December 31, 2019 | 1.392B |
| September 30, 2019 | 1.138B |
| June 30, 2019 | 914.00M |
| March 31, 2019 | -351.00M |
| December 31, 2018 | 2.266B |
| September 30, 2018 | 499.00M |
| June 30, 2018 | 153.00M |
| March 31, 2018 | -107.72M |
| December 31, 2017 | 1.043B |
| September 30, 2017 | 2.286B |
| June 30, 2017 | 280.00M |
| March 31, 2017 | 133.00M |
| December 31, 2016 | 1.995B |
| September 30, 2016 | 839.83M |
| June 30, 2016 | 199.41M |
| March 31, 2016 | 1.223B |
| December 31, 2015 | 592.00M |
| September 30, 2015 | 1.788B |
| June 30, 2015 | 1.099B |
| March 31, 2015 | -32.00M |
| December 31, 2014 | 1.880B |
| September 30, 2014 | 1.978B |
| June 30, 2014 | 2.118B |
| March 31, 2014 | 1.222B |
| December 31, 2013 | 2.511B |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| GSK Plc | 3.386B |
| Johnson & Johnson | 8.616B |
| Eli Lilly & Co. | 10.69B |
| Merck & Co., Inc. | 5.37B |
| Novo Nordisk A/S | 8.364B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -1.856B |
| Cash from Financing (Quarterly) | 266.55M |
| Free Cash Flow | 8.051B |
| Free Cash Flow Per Share (Quarterly) | 0.6037 |
| Free Cash Flow to Equity (Quarterly) | -2.411B |
| Free Cash Flow to Firm (Quarterly) | 2.194B |
| Free Cash Flow Yield | 1.59% |